| Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis A Viloria-Petit, T Crombet, S Jothy, D Hicklin, P Bohlen, JM Schlaeppi, ... Cancer research 61 (13), 5090-5101, 2001 | 688 | 2001 |
| Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer … T Crombet, M Osorio, T Cruz, C Roca, R del Castillo, R Mon, ... Journal of Clinical Oncology 22 (9), 1646-1654, 2004 | 402 | 2004 |
| Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin MS Ramakrishnan, A Eswaraiah, T Crombet, P Piedra, G Saurez, H Iyer, ... MAbs 1 (1), 41-48, 2009 | 292 | 2009 |
| Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer EN Vinageras, A de la Torre, MO Rodríguez, MC Ferrer, I Bravo, ... Journal of clinical oncology 26 (9), 1452-1458, 2008 | 261 | 2008 |
| Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibody T Crombet‐Ramos, J Rak, R Perez, A Viloria‐Petit International journal of cancer 101 (6), 567-575, 2002 | 230 | 2002 |
| Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck MO Rodríguez, TC Rivero, R del Castillo Bahi, CR Muchuli, MA Bilbao, ... Cancer biology & therapy 9 (5), 343-349, 2010 | 226 | 2010 |
| Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial T Crombet Ramos, J Figueredo, M Catala, G Sandra, JC Selva, TM Cruz, ... Cancer biology & therapy 5 (4), 375-379, 2006 | 214 | 2006 |
| A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial G Gonzalez, T Crombet, M Catala, V Mirabal, JC Hernandez, Y González, ... Annals of oncology 9 (4), 431-435, 1998 | 195 | 1998 |
| Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile G Garrido, IA Tikhomirov, A Rabasa, E Yang, E Gracia, N Iznaga, ... Cancer biology & therapy 11 (4), 373-382, 2011 | 169 | 2011 |
| A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non–small cell lung cancer patients PC Rodriguez, X Popa, O Martínez, S Mendoza, E Santiesteban, ... Clinical Cancer Research 22 (15), 3782-3790, 2016 | 166 | 2016 |
| Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy G Gonzalez, T Crombet, F Torres, M Catala, L Alfonso, M Osorio, ... Annals of Oncology 14 (3), 461-466, 2003 | 155 | 2003 |
| Effective Inhibition of the Epidermal Growth Factor/Epidermal Growth Factor Receptor Binding by Anti–Epidermal Growth Factor Antibodies Is Related to Better Survival in … B Garcia, E Neninger, A de la Torre, I Leonard, R Martinez, C Viada, ... Clinical Cancer Research 14 (3), 840-846, 2008 | 150 | 2008 |
| Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer T Crombet, L Torres, E Neninger, M Catalá, ME Solano, A Perera, ... Journal of Immunotherapy 26 (2), 139-148, 2003 | 148 | 2003 |
| A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non–small cell lung cancer patients S Alfonso, A Valdés-Zayas, ER Santiesteban, YI Flores, F Areces, ... Clinical Cancer Research 20 (14), 3660-3671, 2014 | 133 | 2014 |
| Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial MT Solomón, JC Selva, J Figueredo, J Vaquer, C Toledo, N Quintanal, ... BMC cancer 13, 1-8, 2013 | 103 | 2013 |
| Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation … M Ramos-Suzarte, P Lorenzo-Luaces, NG Lazo, ML Perez, JL Soriano, ... Cancer biology & therapy 13 (8), 600-605, 2012 | 100 | 2012 |
| Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study F Rojo, E Gracias, N Villena, T Cruz, JM Corominas, I Corradino, ... Clinical Cancer Research 16 (8), 2474-2482, 2010 | 99 | 2010 |
| Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials G González, T Crombet, E Neninger, C Viada, A Lage Human vaccines 3 (1), 8-13, 2007 | 95 | 2007 |
| Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial T Crombet Ramos, EN Vinageras, M Catalá Ferrer, B García Verdecia, ... Cancer biology & therapy 5 (2), 145-149, 2006 | 88 | 2006 |
| Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer E Neninger, BG Verdecia, T Crombet, C Viada, S Pereda, I Leonard, ... Journal of immunotherapy 32 (1), 92-99, 2009 | 86 | 2009 |
